1. Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

2. This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. Checkpoint Inhibitors in Pancreatic Cancer

5. Ipilimumab + Gemcitabine

6. Tremelimumab + Gemcitabine

7. Nivolumab + Chemotherapy

8. Pembrolizumab + Reovirus + Chemotherapy

9. Indoximod + Chemotherapy

10. Anti-CD40 + Gemcitabine

11. CAR T Cells

12. Ongoing Studies

13. Concluding Remarks

14. Abbreviations

15. Abbreviations (cont)